Zacks Research Forecasts Reduced Earnings for Bone Biologics

Bone Biologics Corp. (NASDAQ:BBLG) – Equities researchers at Zacks Research decreased their Q3 2026 EPS estimates for Bone Biologics in a report released on Monday, August 17th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings of ($0.19) per share for the quarter, down from their prior estimate of ($0.18). The consensus estimate for Bone Biologics’ current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Bone Biologics’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($0.67) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday, July 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Bone Biologics Price Performance

Shares of BBLG opened at $0.64 on Thursday. Bone Biologics has a 1-year low of $0.60 and a 1-year high of $4.13. The company has a 50-day moving average of $1.14 and a 200 day moving average of $1.22. The firm has a market capitalization of $1.16 million, a price-to-earnings ratio of -0.47 and a beta of 0.92.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04).

Institutional Investors Weigh In On Bone Biologics

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC grew its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. 34.30% of the stock is owned by hedge funds and other institutional investors.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.